세계의 길랭 바레 증후군 시장 규모, 점유율 및 동향 분석 : 치료별, 투여 경로별, 유통 채널별, 지역별 전망 및 예측(2023-2030년)

The Global Guillain-Barre Syndrome Market size is expected to reach $852.2 billion by 2030, rising at a market growth of 4.6% CAGR during the forecast period.

North America, particularly the United States and Canada, has a robust healthcare infrastructure with high healthcare spending levels. Thus, the North America segment captured 36.2% revenue share in the market 2022. According to the Government of Canada, since 2014, approximately half of all cases of AFP that have been identified in Canada have been diagnosed with Guillain-Barre syndrome, and approximately twenty percent of those cases have been diagnosed with transverse myelitis.

GBS primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population ages, there's a natural increase in the number of people at risk for GBS, which contributes to the rising prevalence of the condition.

Additionally, according to World Bank data, the World Bank Board of Directors approved US$50 million in new financing for Argentina to improve access to public healthcare services and ensure continued service for 6.5 million residents of the province of Buenos Aires without private health insurance. In conclusion, increasing global healthcare expenditures are driving the market's growth.

However, the acute phase of GBS often requires hospitalization, intensive care, and specialized medical interventions such as plasma exchange and intravenous immunoglobulin (IVIG) therapy. These treatments can incur substantial healthcare costs, including hospital charges, medication expenses, and physician fees, placing financial strain on patients and healthcare systems. Thus, the high cost of treatment is impeding the market's growth.

By Therapeutics Analysis

Based on therapeutics, the market is bifurcated into intravenous immunoglobulin, plasma exchange, and others. In 2022, the intravenous immunoglobulin segment garnered 50.9% revenue share in the market. Intravenous immunoglobulin exerts its therapeutic effects through multiple mechanisms, including modulating immune responses.

By Route Of Administration Analysis

On the basis of the route of administration, the market is segmented into parenteral and oral. In 2022, the oral segment attained a noteworthy revenue share in the market. Oral medications are increasingly utilized for early intervention in GBS cases with mild symptoms or as maintenance therapy following the acute phase of the disease.

By Distribution Channel Analysis

Based on distribution channel, the market is categorized into retail pharmacies, hospital pharmacies, and others. In 2022, the hospital pharmacies segment registered 48.8% revenue share in the market. GBS management typically involves a multidisciplinary team of healthcare professionals, including neurologists, intensivists, physiotherapists, and pharmacists, working together to provide comprehensive patient care.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated 28.2% revenue share in the market. The diagnostic rate of neurological illnesses, including GBS, has improved in the Asia-Pacific region due to increased public and healthcare professional knowledge.

List of Key Companies Profiled

• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• PTC, Inc.
• AstraZeneca PLC
• Novartis AG
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Merck & Co., Inc.
• Bristol Myers Squibb Company

Global Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

• Intravenous Immunoglobulin
• Plasma Exchange
• Others

By Route Of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Guillain-Barre Syndrome Market, by Therapeutics
  • 1.4.2Global Guillain-Barre Syndrome Market, by Route Of Administration
  • 1.4.3Global Guillain-Barre Syndrome Market, by Distribution Channel
  • 1.4.4Global Guillain-Barre Syndrome Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Restraints
  • 3.2.3Market Opportunities
  • 3.2.4Market Challenges
• 3.3Porter Five Forces Analysis

Chapter 4.Global Guillain-Barre Syndrome Market by Therapeutics

• 4.1Global Intravenous Immunoglobulin Market by Region
• 4.2Global Plasma Exchange Market by Region
• 4.3Global Others Market by Region

Chapter 5.Global Guillain-Barre Syndrome Market by Route Of Administration

• 5.1Global Parenteral Market by Region
• 5.2Global Oral Market by Region

Chapter 6.Global Guillain-Barre Syndrome Market by Distribution Channel

• 6.1Global Hospital Pharmacies Market by Region
• 6.2Global Retail Pharmacies Market by Region
• 6.3Global Others Market by Region

Chapter 7.Global Guillain-Barre Syndrome Market by Region

• 7.1North America Guillain-Barre Syndrome Market
  • 7.1.1North America Guillain-Barre Syndrome Market by Therapeutics
    • 7.1.1.1North America Intravenous Immunoglobulin Market by Country
    • 7.1.1.2North America Plasma Exchange Market by Country
    • 7.1.1.3North America Others Market by Country
  • 7.1.2North America Guillain-Barre Syndrome Market by Route Of Administration
    • 7.1.2.1North America Parenteral Market by Country
    • 7.1.2.2North America Oral Market by Country
  • 7.1.3North America Guillain-Barre Syndrome Market by Distribution Channel
    • 7.1.3.1North America Hospital Pharmacies Market by Country
    • 7.1.3.2North America Retail Pharmacies Market by Country
    • 7.1.3.3North America Others Market by Country
  • 7.1.4North America Guillain-Barre Syndrome Market by Country
    • 7.1.4.1US Guillain-Barre Syndrome Market
      • 7.1.4.1.1US Guillain-Barre Syndrome Market by Therapeutics
      • 7.1.4.1.2US Guillain-Barre Syndrome Market by Route Of Administration
      • 7.1.4.1.3US Guillain-Barre Syndrome Market by Distribution Channel
    • 7.1.4.2Canada Guillain-Barre Syndrome Market
      • 7.1.4.2.1Canada Guillain-Barre Syndrome Market by Therapeutics
      • 7.1.4.2.2Canada Guillain-Barre Syndrome Market by Route Of Administration
      • 7.1.4.2.3Canada Guillain-Barre Syndrome Market by Distribution Channel
    • 7.1.4.3Mexico Guillain-Barre Syndrome Market
      • 7.1.4.3.1Mexico Guillain-Barre Syndrome Market by Therapeutics
      • 7.1.4.3.2Mexico Guillain-Barre Syndrome Market by Route Of Administration
      • 7.1.4.3.3Mexico Guillain-Barre Syndrome Market by Distribution Channel
    • 7.1.4.4Rest of North America Guillain-Barre Syndrome Market
      • 7.1.4.4.1Rest of North America Guillain-Barre Syndrome Market by Therapeutics
      • 7.1.4.4.2Rest of North America Guillain-Barre Syndrome Market by Route Of Administration
      • 7.1.4.4.3Rest of North America Guillain-Barre Syndrome Market by Distribution Channel
• 7.2Europe Guillain-Barre Syndrome Market
  • 7.2.1Europe Guillain-Barre Syndrome Market by Therapeutics
    • 7.2.1.1Europe Intravenous Immunoglobulin Market by Country
    • 7.2.1.2Europe Plasma Exchange Market by Country
    • 7.2.1.3Europe Others Market by Country
  • 7.2.2Europe Guillain-Barre Syndrome Market by Route Of Administration
    • 7.2.2.1Europe Parenteral Market by Country
    • 7.2.2.2Europe Oral Market by Country
  • 7.2.3Europe Guillain-Barre Syndrome Market by Distribution Channel
    • 7.2.3.1Europe Hospital Pharmacies Market by Country
    • 7.2.3.2Europe Retail Pharmacies Market by Country
    • 7.2.3.3Europe Others Market by Country
  • 7.2.4Europe Guillain-Barre Syndrome Market by Country
    • 7.2.4.1Germany Guillain-Barre Syndrome Market
      • 7.2.4.1.1Germany Guillain-Barre Syndrome Market by Therapeutics
      • 7.2.4.1.2Germany Guillain-Barre Syndrome Market by Route Of Administration
      • 7.2.4.1.3Germany Guillain-Barre Syndrome Market by Distribution Channel
    • 7.2.4.2UK Guillain-Barre Syndrome Market
      • 7.2.4.2.1UK Guillain-Barre Syndrome Market by Therapeutics
      • 7.2.4.2.2UK Guillain-Barre Syndrome Market by Route Of Administration
      • 7.2.4.2.3UK Guillain-Barre Syndrome Market by Distribution Channel
    • 7.2.4.3France Guillain-Barre Syndrome Market
      • 7.2.4.3.1France Guillain-Barre Syndrome Market by Therapeutics
      • 7.2.4.3.2France Guillain-Barre Syndrome Market by Route Of Administration
      • 7.2.4.3.3France Guillain-Barre Syndrome Market by Distribution Channel
    • 7.2.4.4Russia Guillain-Barre Syndrome Market
      • 7.2.4.4.1Russia Guillain-Barre Syndrome Market by Therapeutics
      • 7.2.4.4.2Russia Guillain-Barre Syndrome Market by Route Of Administration
      • 7.2.4.4.3Russia Guillain-Barre Syndrome Market by Distribution Channel
    • 7.2.4.5Spain Guillain-Barre Syndrome Market
      • 7.2.4.5.1Spain Guillain-Barre Syndrome Market by Therapeutics
      • 7.2.4.5.2Spain Guillain-Barre Syndrome Market by Route Of Administration
      • 7.2.4.5.3Spain Guillain-Barre Syndrome Market by Distribution Channel
    • 7.2.4.6Italy Guillain-Barre Syndrome Market
      • 7.2.4.6.1Italy Guillain-Barre Syndrome Market by Therapeutics
      • 7.2.4.6.2Italy Guillain-Barre Syndrome Market by Route Of Administration
      • 7.2.4.6.3Italy Guillain-Barre Syndrome Market by Distribution Channel
    • 7.2.4.7Rest of Europe Guillain-Barre Syndrome Market
      • 7.2.4.7.1Rest of Europe Guillain-Barre Syndrome Market by Therapeutics
      • 7.2.4.7.2Rest of Europe Guillain-Barre Syndrome Market by Route Of Administration
      • 7.2.4.7.3Rest of Europe Guillain-Barre Syndrome Market by Distribution Channel
• 7.3Asia Pacific Guillain-Barre Syndrome Market
  • 7.3.1Asia Pacific Guillain-Barre Syndrome Market by Therapeutics
    • 7.3.1.1Asia Pacific Intravenous Immunoglobulin Market by Country
    • 7.3.1.2Asia Pacific Plasma Exchange Market by Country
    • 7.3.1.3Asia Pacific Others Market by Country
  • 7.3.2Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration
    • 7.3.2.1Asia Pacific Parenteral Market by Country
    • 7.3.2.2Asia Pacific Oral Market by Country
  • 7.3.3Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel
    • 7.3.3.1Asia Pacific Hospital Pharmacies Market by Country
    • 7.3.3.2Asia Pacific Retail Pharmacies Market by Country
    • 7.3.3.3Asia Pacific Others Market by Country
  • 7.3.4Asia Pacific Guillain-Barre Syndrome Market by Country
    • 7.3.4.1China Guillain-Barre Syndrome Market
      • 7.3.4.1.1China Guillain-Barre Syndrome Market by Therapeutics
      • 7.3.4.1.2China Guillain-Barre Syndrome Market by Route Of Administration
      • 7.3.4.1.3China Guillain-Barre Syndrome Market by Distribution Channel
    • 7.3.4.2Japan Guillain-Barre Syndrome Market
      • 7.3.4.2.1Japan Guillain-Barre Syndrome Market by Therapeutics
      • 7.3.4.2.2Japan Guillain-Barre Syndrome Market by Route Of Administration
      • 7.3.4.2.3Japan Guillain-Barre Syndrome Market by Distribution Channel
    • 7.3.4.3India Guillain-Barre Syndrome Market
      • 7.3.4.3.1India Guillain-Barre Syndrome Market by Therapeutics
      • 7.3.4.3.2India Guillain-Barre Syndrome Market by Route Of Administration
      • 7.3.4.3.3India Guillain-Barre Syndrome Market by Distribution Channel
    • 7.3.4.4South Korea Guillain-Barre Syndrome Market
      • 7.3.4.4.1South Korea Guillain-Barre Syndrome Market by Therapeutics
      • 7.3.4.4.2South Korea Guillain-Barre Syndrome Market by Route Of Administration
      • 7.3.4.4.3South Korea Guillain-Barre Syndrome Market by Distribution Channel
    • 7.3.4.5Singapore Guillain-Barre Syndrome Market
      • 7.3.4.5.1Singapore Guillain-Barre Syndrome Market by Therapeutics
      • 7.3.4.5.2Singapore Guillain-Barre Syndrome Market by Route Of Administration
      • 7.3.4.5.3Singapore Guillain-Barre Syndrome Market by Distribution Channel
    • 7.3.4.6Malaysia Guillain-Barre Syndrome Market
      • 7.3.4.6.1Malaysia Guillain-Barre Syndrome Market by Therapeutics
      • 7.3.4.6.2Malaysia Guillain-Barre Syndrome Market by Route Of Administration
      • 7.3.4.6.3Malaysia Guillain-Barre Syndrome Market by Distribution Channel
    • 7.3.4.7Rest of Asia Pacific Guillain-Barre Syndrome Market
      • 7.3.4.7.1Rest of Asia Pacific Guillain-Barre Syndrome Market by Therapeutics
      • 7.3.4.7.2Rest of Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration
      • 7.3.4.7.3Rest of Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel
• 7.4LAMEA Guillain-Barre Syndrome Market
  • 7.4.1LAMEA Guillain-Barre Syndrome Market by Therapeutics
    • 7.4.1.1LAMEA Intravenous Immunoglobulin Market by Country
    • 7.4.1.2LAMEA Plasma Exchange Market by Country
    • 7.4.1.3LAMEA Others Market by Country
  • 7.4.2LAMEA Guillain-Barre Syndrome Market by Route Of Administration
    • 7.4.2.1LAMEA Parenteral Market by Country
    • 7.4.2.2LAMEA Oral Market by Country
  • 7.4.3LAMEA Guillain-Barre Syndrome Market by Distribution Channel
    • 7.4.3.1LAMEA Hospital Pharmacies Market by Country
    • 7.4.3.2LAMEA Retail Pharmacies Market by Country
    • 7.4.3.3LAMEA Others Market by Country
  • 7.4.4LAMEA Guillain-Barre Syndrome Market by Country
    • 7.4.4.1Brazil Guillain-Barre Syndrome Market
      • 7.4.4.1.1Brazil Guillain-Barre Syndrome Market by Therapeutics
      • 7.4.4.1.2Brazil Guillain-Barre Syndrome Market by Route Of Administration
      • 7.4.4.1.3Brazil Guillain-Barre Syndrome Market by Distribution Channel
    • 7.4.4.2Argentina Guillain-Barre Syndrome Market
      • 7.4.4.2.1Argentina Guillain-Barre Syndrome Market by Therapeutics
      • 7.4.4.2.2Argentina Guillain-Barre Syndrome Market by Route Of Administration
      • 7.4.4.2.3Argentina Guillain-Barre Syndrome Market by Distribution Channel
    • 7.4.4.3UAE Guillain-Barre Syndrome Market
      • 7.4.4.3.1UAE Guillain-Barre Syndrome Market by Therapeutics
      • 7.4.4.3.2UAE Guillain-Barre Syndrome Market by Route Of Administration
      • 7.4.4.3.3UAE Guillain-Barre Syndrome Market by Distribution Channel
    • 7.4.4.4Saudi Arabia Guillain-Barre Syndrome Market
      • 7.4.4.4.1Saudi Arabia Guillain-Barre Syndrome Market by Therapeutics
      • 7.4.4.4.2Saudi Arabia Guillain-Barre Syndrome Market by Route Of Administration
      • 7.4.4.4.3Saudi Arabia Guillain-Barre Syndrome Market by Distribution Channel
    • 7.4.4.5South Africa Guillain-Barre Syndrome Market
      • 7.4.4.5.1South Africa Guillain-Barre Syndrome Market by Therapeutics
      • 7.4.4.5.2South Africa Guillain-Barre Syndrome Market by Route Of Administration
      • 7.4.4.5.3South Africa Guillain-Barre Syndrome Market by Distribution Channel
    • 7.4.4.6Nigeria Guillain-Barre Syndrome Market
      • 7.4.4.6.1Nigeria Guillain-Barre Syndrome Market by Therapeutics
      • 7.4.4.6.2Nigeria Guillain-Barre Syndrome Market by Route Of Administration
      • 7.4.4.6.3Nigeria Guillain-Barre Syndrome Market by Distribution Channel
    • 7.4.4.7Rest of LAMEA Guillain-Barre Syndrome Market
      • 7.4.4.7.1Rest of LAMEA Guillain-Barre Syndrome Market by Therapeutics
      • 7.4.4.7.2Rest of LAMEA Guillain-Barre Syndrome Market by Route Of Administration
      • 7.4.4.7.3Rest of LAMEA Guillain-Barre Syndrome Market by Distribution Channel

Chapter 8.Company Profiles

• 8.1F. Hoffmann-La Roche Ltd.
  • 8.1.1Company Overview
  • 8.1.2Financial Analysis
  • 8.1.3Segmental and Regional Analysis
  • 8.1.4Research & Development Expense
  • 8.1.5SWOT Analysis
• 8.2Pfizer, Inc.
  • 8.2.1Company Overview
  • 8.2.2Financial Analysis
  • 8.2.3Regional & Segmental Analysis
  • 8.2.4Research & Development Expense
  • 8.2.5SWOT Analysis
• 8.3PTC, Inc.
  • 8.3.1Company Overview
  • 8.3.2Financial Analysis
  • 8.3.3Segmental and Regional Analysis
  • 8.3.4Research & Development Expenses
  • 8.3.5SWOT Analysis
• 8.4AstraZeneca PLC
  • 8.4.1Company Overview
  • 8.4.2Financial Analysis
  • 8.4.3Regional Analysis
  • 8.4.4Research & Development Expenses
  • 8.4.5SWOT Analysis
• 8.5Novartis AG
  • 8.5.1Company Overview
  • 8.5.2Financial Analysis
  • 8.5.3Segmental and Regional Analysis
  • 8.5.4Research & Development Expense
  • 8.5.5Recent strategies and developments:
    • 8.5.5.1Partnerships, Collaborations, and Agreements:
  • 8.5.6SWOT Analysis
• 8.6Novo Nordisk A/S
  • 8.6.1Company Overview
  • 8.6.2Financial Analysis
  • 8.6.3Segmental and Regional Analysis
  • 8.6.4Research & Development Expenses
  • 8.6.5SWOT Analysis
• 8.7Takeda Pharmaceutical Company Limited
  • 8.7.1Company Overview
  • 8.7.2Financial Analysis
  • 8.7.3Regional Analysis
  • 8.7.4Research & Development Expense
  • 8.7.5SWOT Analysis
• 8.8Bayer AG
  • 8.8.1Company Overview
  • 8.8.2Financial Analysis
  • 8.8.3Segmental and Regional Analysis
  • 8.8.4Research & Development Expense
  • 8.8.5SWOT Analysis
• 8.9Merck & Co., Inc.
  • 8.9.1Company Overview
  • 8.9.2Financial Analysis
  • 8.9.3Segmental and Regional Analysis
  • 8.9.4Research & Development Expenses
  • 8.9.5Recent strategies and developments:
    • 8.9.5.1Partnerships, Collaborations, and Agreements:
  • 8.9.6SWOT Analysis
• 8.10.Bristol Myers Squibb Company
  • 8.10.1Company Overview
  • 8.10.2Financial Analysis
  • 8.10.3Regional Analysis
  • 8.10.4Research & Development Expenses
  • 8.10.5SWOT Analysis

Chapter 9.Winning Imperatives of Guillain-Barre Syndrome Market